Results 51 to 60 of about 648 (164)

Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? [PDF]

, 2021
BACKGROUND: Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action.
Campelj, Dean G, Fischer, Dirk, Gueven, Nuri, Hafner, P, Kourakis, S, Rybalka, Emma, Timpani, Cara   +6 more
core   +3 more sources

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis [PDF]

, 2022
Cladribine tablets; Relapsing multiple sclerosis; Treatment satisfactionComprimidos de cladribina; Esclerosis múltiple recurrente; Satisfacción con el tratamientoComprimits de cladribina; Esclerosi múltiple recurrent; Satisfacció amb el ...
Brochet, Bruno, Hupperts, Raymond, Langdon, Dawn, Lechner-Scott, Jeannette, Montalban Gairín, Xavier, Piehl, Fredrik, Solari, Alessandra   +6 more
core   +1 more source

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases [PDF]

, 2019
The transcription factor NF-E2 p45-related factor 2 (NRF2; encoded by NFE2L2) and its principal negative regulator, the E3 ligase adaptor Kelch-like ECH-associated protein 1 (KEAP1), are critical in the maintenance of redox, metabolic and protein ...
Attucks, Otis C., Cousin, Sharon P., Cuadrado, Antonio, Dinkova-Kostova, Albena, Franklin, Stephen, Hayes, John, Kensler, Thomas W., Levonen, Anna-Liisa, Rojo, Ana I., Rumsey, William L., Wells, Geoffrey   +10 more
core   +2 more sources

Recent advances in the management of multiple sclerosis [PDF]

, 2022
Every 5 minutes, someone somewhere in the world is diagnosed with an inflammatory, demyelinating, neurodegenerative disorder known as multiple sclerosis (MS). MS was historically known as "La sclèrose en plaques" which involves the central nervous system
Deva, Reka, Rajendran, Priyadharsini
core   +2 more sources

Large-scale cross-sectional online survey on patient-neurologist communication, burden of disease assessment and disease monitoring in people with multiple sclerosis [PDF]

, 2023
Background Management of multiple sclerosis (MS) requires a high level of communication between health care professionals (HCPs) and people with MS (pwMS) including profound investigation and discussion of symptoms to identify therapeutic needs.
Bayas, Antonios, Christ, Monika, Schuh, Katrin   +2 more
core   +1 more source

The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis [PDF]

Multiple sclerosis is the most common autoimmune disease affecting the central nervous system (CNS) worldwide. Multiple sclerosis involves inflammatory demyelination of nerve fibers in the CNS, often presenting with recurrent episodes of focal sensory or
Ahmadzadeh, Shahab, Anderson, Lillian, Askins, Dorothy H, Boggio, Nicole A, Fazal, Ahmed, Kaye, Adam M, Kaye, Alan D, Lacey, John, Le, Viet, Mosieri, Chizoba N, Paladini, Antonella, Robinson, Christopher L, Shekoohi, Sahar, Varrassi, Giustino   +13 more
core   +2 more sources

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau, Nicoletta Luxi, Fabio Riefolo, Martín Solorzano, Irene Pazos, Elena Ballarín, Lise Skovgaard Svingel, Lorenzo Chiusaroli, Elisa Martín‐Merino, Elisa Barbieri, María Lopez‐Lasanta, Sima Mohammadi, Denis Rotta, Alexandra Pacurariu, Catherine Cohet, Miriam Sturkenboom, Carlos E. Durán, on behalf of the SAFETY‐VAC study consortium, Carlos E. Durán, Miriam Sturkenboom, Judit Riera‐Arnau, Nicoletta Luxi, Olaf Klungel, Patrick Souverein, Sima Mohammadi, Fabio Riefolo, Irene Pazos, Rosa Gini, Davide Messina, Giuseppe Roberto, Carlo Giaquinto, Elisa Barbieri, Luca Stona, Felipe Villalobos, Martín Solorzano, Carlo Alberto Bissacco, Antonio Gimeno, Beatriz Poblador, Mercedes Aza, Aida Moreno, Alejandro Santos, Vera Ehrenstein, Lise Skovgaard Svingel, Benjamin Randeris Johannesen, Cécile Droz‐Perroteau, Laure Carcaillon‐Bentata, Anna‐Mija Tolppanen, Sirpa Hartikainen, Thuan Vo, Anne Paakinaho, Blair Rajamaki, Hedvig Nordeng, Saeed Hayati, Mahmoud Zidan, Juan José Carreras Martínez, Arantxa Urchueguía Fornes, Elisa Correcher Martínez, Javier Díez‐Domingo, Mar Martin, Patricia Garcia‐Poza, Airam de Burgos, Belén Castillo‐Cano, Elisa Martín‐Merino   +62 more
wiley   +1 more source

Recommendations for the Treatment of Multiple Sclerosis in Family Planning, Pregnancy and Lactation in Switzerland: Immunotherapy [PDF]

A large number of disease-modifying immunotherapies are available for the treatment of people with multiple sclerosis. Many disease-modifying immunotherapies show scarce or no safety data in pregnancy and breastfeeding and are labeled as being ...
Bigi, Sandra, Chan, Andrew, Derfuss, Tobias, Diem, Lara, Do Canto, Philipp, Friedli, Christoph, Gobbi, Claudio, Graber, Michael, Granziera, Cristina, Hammer, Helly Noemi, Hoepner, Robert, Jelcic, Ilijas, Kamber, Nicole, Kana, Veronika, Kuhle, Jens, Legardeur, Helene, Müller, Stefanie, Panchaud, Alice, Pot, Caroline, Salmen, Anke, Surbek, Daniel, Théaudin, Marie, Zecca, Chiara   +22 more
core   +1 more source

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

Annals of Clinical and Translational Neurology, Volume 12, Issue 11, Page 2214-2225, November 2025.
ABSTRACT Objective Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age‐ and BMI‐adjusted) with absolute concentrations for the prediction of response to disease‐modifying therapy.
Maximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, Johanna Oechtering, Sabine Schaedelin, Lisa Hofer, Amar Zadic, Juan Francisco Vilchez Gomez, Lester Melie‐Garcia, Alessandro Cagol, Riccardo Galbusera, Sebastian Finkener, Patrice Lalive, Marjolaine Uginet, Stefanie Müller, Caroline Pot, Amandine Mathias, Renaud Du Pasquier, Robert Hoepner, Andrew Chan, Giulio Disanto, Chiara Zecca, Marcus D’Souza, Lars G. Hemkens, Tobias Derfuss, Özgür Yaldizli, Patrick Roth, Claudio Gobbi, David Brassat, Björn Tackenberg, Henrik Zetterberg, Tjalf Ziemssen, Heinz Wiendl, Klaus Berger, Marco Hermesdorf, Fredrik Piehl, Ludwig Kappos, Cristina Granziera, Ahmed Abdelhak, David Leppert, Eline A. J. Willemse, Pascal Benkert, Jens Kuhle, Swiss Multiple Sclerosis Cohort Study (SMSC)   +43 more
wiley   +1 more source

Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease‐Modifying Treatments for Multiple Sclerosis

European Journal of Neurology, Volume 32, Issue 11, November 2025.
ABSTRACT Background Regenerative strategies in progressive multiple sclerosis (MS) pose a significant unmet need. Combining immunomodulatory treatment with remyelinating interventions to target the complex underlying pathogenesis appeals as the next frontier in MS therapeutic developments.
Anna‐Victoria De Keersmaecker, Eline van Doninck, Inez Wens, Yousra El Ouaamari, Veronica Popescu, Guy Laureys, Melissa Cambron, Miguel D'Haeseleer, Lander Willem, Judith Derdelinckx, Tatjana Reynders, Barbara Willekens   +11 more
wiley   +1 more source